The progress has been encouraging with approvals and launches in the US, EU, Japan, Australia and Emerging Markets. Post Mylan Upjohn (Pfizer) merger, the scope has been extended to China as well.
While top industry leaders are optimistic about the growth, they expect the special incentives and regulatory streamlining from the government’s side
The partnership is a significant step in delivering advanced cancer therapies to patients.
Dr Christiane Hamacher, has stepped down as the MD of Biocon Biologics and will be succeeded by Dr Arun Chandavarkar.
After a volatile decade in which approvals swung sharply from year to year, 2025’s total pushed past long-term norms, exceeding the 10-year average
As per the Department of Pharmaceuticals, the sector has expanded its reach across the country while strengthening domestic production capabilities and innovation
MabionCD20 is a monoclonal antibody originally developed by Mabion as a biosimilar candidate to MabThera and Rituxan therapies
Knowledge paper highlights biosimilars, biologics, AI-driven drug discovery and regulatory excellence as key growth drivers for the next phase of India's pharma expansion
The union minister spoke at the 2nd Pharma Summit & Awards 2026 organised by ASSOCHAM in New Delhi
Ranluspec is the only interchangeable ranibizumab biosimilar approved in the United States in both vial and pre-filled syringe (PFS) presentations
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
